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REVIEW
Exploring the HIFs, buts and maybes of hypoxia signalling in
disease: lessons from zebrafish models
Philip M. Elks1,2,*, Stephen A. Renshaw1,2, Annemarie H. Meijer3, Sarah R. Walmsley4 and
Fredericus J. van Eeden2
ABSTRACT
A low level of tissue oxygen (hypoxia) is a physiological feature of a
wide range of diseases, from cancer to infection. Cellular hypoxia is
sensed by oxygen-sensitive hydroxylase enzymes, which regulate
the protein stability of hypoxia-inducible factor α (HIF-α) transcription
factors. When stabilised, HIF-α binds with its cofactors to HIF-
responsive elements (HREs) in the promoters of target genes to
coordinate a wide-ranging transcriptional programme in response to
the hypoxic environment. This year marks the 20th anniversary of the
discovery of the HIF-1α transcription factor, and in recent years the
HIF-mediated hypoxia response is being increasingly recognised as
an important process in determining the outcome of diseases such as
cancer, inflammatory disease and bacterial infections. Animalmodels
have shed light on the roles of HIF in disease and have uncovered
intricate control mechanisms that involve multiple cell types,
observations that might have been missed in simpler in vitro
systems. These findings highlight the need for new whole-organism
models of disease to elucidate these complex regulatory
mechanisms. In this Review, we discuss recent advances in our
understanding of hypoxia and HIFs in disease that have emerged
from studies of zebrafish disease models. Findings from suchmodels
identify HIF as an integral player in the disease processes. They also
highlight HIF pathway components and their targets as potential
therapeutic targets against conditions that range from cancers to
infectious disease.
KEY WORDS: Disease models, Hypoxia, Hypoxia-inducible factor,
Zebrafish
Introduction
Cellular and tissue hypoxia are an everyday occurrence that
cells must respond to rapidly in order to avoid metabolic
shutdown and consequent death. All mammals control the cellular
response to low oxygen levels through regulation of the hypoxia-
inducible factor α (HIF-α) transcription factor family (members of
which are discussed in more detail below). Unlike many
transcription factors, the levels of HIF-α are primarily controlled
post-translationally. HIF-α protein activity is controlled by two
families of oxygen-sensing hydroxylases: prolyl hydroxylase
domain-containing proteins (PHDs) and factor inhibiting
HIF (FIH) (Epstein et al., 2001; Lando et al., 2002). In normoxia,
PHDs hydroxylate HIF-α and target it for proteasomal degradation,
which is facilitated by the binding of von Hippel-Lindau
tumour suppressor (pVHL) protein. In hypoxia, PHD enzyme
activity is reduced, owing to the oxygen requirement of the
hydroxylase activity, and HIF-α is stabilised (Huang et al., 1998;
Kallio et al., 1999). Once stabilised, the HIF-α subunit forms a
nuclear heterodimeric complex with its constitutively stable
counterpart HIF-β [or aryl hydrocarbon nuclear translocator
(ARNT)] to transcribe target genes that contain a HIF-responsive
element (HRE) in their regulatory regions (Huang et al.,
1996; Kaelin and Ratcliffe, 2008; Semenza and Wang, 1992;
Wenger, 2002).
This year, 2015, marks the 20th anniversary of the identification
of HIF-1α as the protein responsible for the cellular response to
hypoxia, and since its discovery it has been implicated in disease
(Wang and Semenza, 1995). Oxygen levels vary greatly in health,
and there are significant oxygen gradients across tissues during
homeostasis (Lokmic et al., 2012). These oxygen gradients are
disrupted in a range of diseases. Modulation of HIF-α has been
mechanistically linked to the progression and severity of a number
of disease processes, including cancer and inflammatory diseases
(Semenza, 2012). Over the last 20 years, major leaps in our
understanding of hypoxia and HIF signalling have emerged from
in vitro cell-culture studies, which offer powerful tools for
investigating hypoxia and the HIF pathway (Bruick and
McKnight, 2001; Chan et al., 2005; Salceda and Caro, 1997). In
disease, tissue hypoxia is generated in a complex tissue
environment, with wide variation in the local levels of oxygen
because of differences in oxygen supply and consumption. In the
last decade, in vivo models have complemented cell-line studies,
giving a more physiologically relevant setting in which to
understand the interrelationship of hypoxia and disease. The most
widely used animal models to understand hypoxia and HIF are
rodents. Mice and rats are highly amenable to manipulation and are
small enough to fit into hypoxic chambers for long periods of time
(Yu and Hales, 2011). The development of Cre-lox conditional
knockout systems in mice has allowed cell- and tissue-specific HIF-
1α and HIF-2α knockout models to be created that have been
instrumental in our understanding of the roles of hypoxia and HIF in
specific cell types and tissues (Cramer et al., 2003; Kapitsinou et al.,
2014; Schipani et al., 2001).
HIF is a major regulator of homeostasis and has wide-ranging
effects: from the cellular level to a local level (for example, in a
tumour) to systemic effects across the entire organism. The zebrafish
(Danio rerio) is a genetically tractable organism that has recently
come to light as a useful model for studying hypoxia and HIF in
disease. A major advantage of zebrafish is that they have optically
transparent larvae, providing an unprecedented opportunity to
visualise disease processes in vivo using fluorescence microscopy,
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from holistic whole-body phenotypes to individual cell behaviour.
Other advantages of the zebrafish system include medium-to-high
throughput drug screening (via addition of small-molecule
compounds to the embryo water; Robertson et al., 2014a) and
genetic tractability [especially with recently improved genome-
editing technology via CRISPR (clustered regularly interspaced
short palindromic repeats)/Cas9 (CRISPR associated protein 9)
technology (see Box 1); Hruscha et al., 2013; Varshney et al., 2015].
Zebrafish have conserved homologues of most human genes and
have all the pathway components of HIF signalling. Initially
employed as a model of developmental biology, in the last 15 years
zebrafish research has extended to include disease modelling, and
there are now numerous diseases modelled in the zebrafish, from
tuberculosis to Parkinson’s disease (Flinn et al., 2008; Renshaw and
Trede, 2012; Torraca et al., 2014).
The mechanisms of hypoxia and HIF stabilisation must be
elucidated further in the context of in vivo disease models to identify
successful avenues for drug discovery and development against
disease. In this Review, we outline the zebrafish models that are
available for investigating hypoxia and HIF in disease settings.
We discuss the conservation of hypoxia-signalling components,
followed by the methods employed to manipulate hypoxia
signalling in live zebrafish models. In the second part of the
Review, we discuss recent advances in hypoxia and disease that
have emerged from zebrafish studies, as well as the challenges
facing this research field. We also assess how zebrafish can be used
to further our understanding of HIF signalling and disease.
Hypoxia signalling in zebrafish
There are three mammalian isoforms of HIF-α, namely HIF-1α,
HIF-2α and HIF-3α (Ema et al., 1997; Gu et al., 1998; Tian et al.,
1997; Wang and Semenza, 1995). The assembly of the HIF
transcription factor in response to low levels of oxygen depends
on the accumulation of the HIF-α subunit (Kaelin and Ratcliffe,
2008). Although many transcription factors are regulated at a
transcriptional level, requiring de novo protein synthesis, HIF-α is
primarily regulated post-translationally to allow for a rapid response
to decreasing oxygen levels (Berra et al., 2001; Moroz et al., 2009;
Wang et al., 1995). HIF biology is well conserved across
vertebrates, with all having at least three HIF-α subtypes, HIF-1α,
HIF-2α and HIF-3α (Hampton-Smith and Peet, 2009). Of these,
HIF-1α and HIF-2α are the best characterised across species and are
the most highly expressed across tissues (Prabhakar and Semenza,
2012). The role of HIF-3α is not yet clear, with multiple splice
variants having opposing effects on HIF-1α and HIF-2α signalling,
some acting as promoters and others as inhibitors (Maynard et al.,
2007, 2003; Zhang et al., 2014).
Zebrafish homologues of HIF-α are referred to as Hif-1αa, Hif-
1αb, Hif-2αa, Hif-2αb, Hif-3αa and Hif-3αb (Fig. 1 and Table 1).
The a and b forms have arisen from a genome duplication event in
the teleost lineage, more than 100 million years ago (Postlethwait
et al., 2000; Rojas et al., 2007; Rytkonen et al., 2013, 2014).
Sequence homology shows that the zebrafish Hif-1αb variant is
more closely related to human HIF-1α than to zebrafish Hif-1αa,
with an amino acid identity of 57.8 and 44.1%, respectively
(Rytkonen et al., 2014). Furthermore, Hif-1αa and b forms are
differentially expressed, with the Hif-1αb homologue being more
highly expressed than Hif-1αa when mRNA levels are assessed by
in situ hybridisation (Elks et al., 2011; Rojas et al., 2007). Hif-1αa
lacks one of the regulatory LXXLAP hydroxylation sites, whereas
Hif-1αb retains both LXXLAP domains (Elks et al., 2011).
Functional expression and overexpression data are consistent with
Hif-1αb being the key zebrafish homologue in the hypoxic
response (Elks et al., 2011; Kopp et al., 2011). Zebrafish Hif-
2αa and Hif-2αb are more closely related to each other than to their
Hif-1α equivalents, both in terms of transcript expression levels
and amino acid identity to human HIF-2α (56.1 and 53.7% amino
acid identity, respectively; Rytkonen et al., 2014). Both have the
two regulatory LXXLAP hydroxylation sites. Although Hif-2αa is
more widely studied in zebrafish (Thompson et al., 2014), there are
no data to suggest that Hif-2αb cannot play an active role in
zebrafish hypoxia signalling. Similar to in mammalian systems,
Hif-3α has multiple splice variants in the zebrafish and is not as
widely studied as Hif-1α and Hif-2α (Zhang et al., 2014). Like Hif-
1α and Hif-2α, Hif-3α is duplicated in the zebrafish, described as
Hif-3αa and Hif-3αb (Rytkonen et al., 2014). A recent antibody
study indicates that all Hif-α proteins are detectable in the zebrafish
embryo from 1 day postfertilisation and suggests that Hif-1αb is the
most upregulated protein in the embryo response to hypoxia
(Koblitz et al., 2015).
In normoxia, PHD enzymes hydroxylate HIF-α on two conserved
prolyl residues in the LXXLAP hydroxylation sites, triggering
binding and ubiquitination by pVHL, leading to the degradation of
HIF-α by the proteasome (Huang et al., 1998; Kallio et al., 1999;
Salceda and Caro, 1997). HIF-α degradation, via hydroxylation by
PHD enzymes, is the major regulatory mechanism for controlling
the HIF response. However, HIF signalling is also fine-tuned by
Box 1. Glossary
Chronic obstructive pulmonary disease (COPD): a condition
characterised by chronic inflammation of the lung airways and alveoli.
Clustered regularly interspaced short palindromic repeats (CRISPR/
Cas9): a genome-editing technology that enables targeted disruption of
the coding sequence of a target gene(s) using an appropriate guide RNA
to direct a Cas9 nuclease to a specific genome location.
Erythropoietin: a glycoprotein hormone that controls erythropoiesis (red
blood cell formation).
Intracellular iron regulatory protein 1 (IRP1): a protein involved in the
control of iron metabolism and in catalysing the conversion of citrate to
isocitrate.
Liposome: a spherical vesicle having at least one lipid bilayer that can be
used as a vehicle for administration of drugs.
Mammalian target of rapamycin (mTOR): a serine/threonine protein
kinase that regulates many cellular processes, including cell growth,
proliferation, motility, survival, protein synthesis, autophagy and
transcription.
Nitric oxide synthase (NOS): an enzyme that catalyses the production
of nitric oxide, an important cellular signalling molecule involved in
wide-ranging physiological responses, including angiogenesis,
neurotransmission and immune defence.
Nuclear factor κ-light-chain-enhancer of activated B cells (NFκB): a
protein complex that plays a key role in regulating the immune response
to infection by regulating the production of cytokines.
Phosphoinositide 3-kinase (PI3K): a family of related intracellular
signal transducer enzymes that phosphorylate the 3-position hydroxyl
group of the inositol ring of phosphatidylinositol, having wide-ranging
cellular effects, including cell growth, proliferation, differentiation, motility,
survival and intracellular trafficking.
Polycythaemia: a condition associated with a high concentration of red
blood cells in the blood.
Polymersomes: artificial vesicles that can contain and deliver drugs.
Single plane illumination microscopy (SPIM): a microscopy method
that employs a sheet of laser light to illuminate the sample.
Transcription activator-like effector nucleases (TALENs): a genome-
editing technology that enables targeted disruption of the coding
sequence of a target gene(s) using an appropriate guide RNA to direct
a Cas9 nuclease to a specific genome location.
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transcriptional regulation of HIF-α and by blocking its transcription
factor activity by a second HIF-α regulatory hydroxylase family
protein, FIH (Lando et al., 2002). The human genome contains
three functional PHD enzyme family members, namely PHD-1
(EGLN2), PHD-2 (EGLN1) and PHD-3 (EGLN3). Zebrafish
have one homologue of each, apart from PHD-2, which is
duplicated: Phd-1 (Egln2), Phd-2a (Egln1a), Phd-2b (Egln1b)
and Phd-3 (Egln3). The functional activity and expression of
Phd enzymes are not widely studied in zebrafish. However, Phd-3 is
the most highly upregulated variant when Hif-α is stabilised in a
Vhl knockout zebrafish line, demonstrating the same negative
feedback loop observed in mammals (Santhakumar et al., 2012; van
Rooijen et al., 2011). Zebrafish have a single homologue of
VHL (Vhl), and a less well-characterised VHL-like gene (vll)
(Metelo et al., 2015; van Rooijen et al., 2011, 2010, 2009).
Zebrafish Vhl shares 52% amino acid identity with human VHL,
and knockout studies indicate that it is functional in the hypoxic
response (van Rooijen et al., 2010). Zebrafish have one functional
homologue of FIH (Fih) that is highly conserved with the human
protein, with 79% amino acid identity. The function of Fih in
negatively regulating Hif has yet to be confirmed in the zebrafish,
but functional conservation is suggested at the protein structure
level, with the enzymatically active Jumonji (JmjC) domain
having 96% homology to that in human FIH (So et al., 2014).
Furthermore, the transcript expression of fih-1 is comparable to that
of vhl and hif-1αb at later stages of development (25 and 36 h
postfertilisation), indicating a functional role in hypoxia signalling
(So et al., 2014).
In hypoxia, the hydroxylases are silenced, which results in the
stabilisation of HIF-α. Knockdown studies have demonstrated that,
as in humans, zebrafish Hif-α must bind to its partner, Arnt, as a
heteromer to signal (Elks et al., 2011; Prasch et al., 2006). Zebrafish
have two Arnt1 homologues, Arnt1a and Arnt1b, with the shorter
Arnt1a form seemingly non-functional in in vitro studies (Prasch
et al., 2006). The conservation of the HIF-signalling components in
the zebrafish extends to the level of HIF-responsive elements
(HREs) in promoters of known HIF targets, including Phd-3 and
insulin-like growth factor binding protein-1, among others (Egg
Table 1. Zebrafish tools for Hif manipulation and analysis
Method Administration Effect on Hif References
Physical hypoxia Embryos placed in hypoxic chamber
at ≤5% oxygen
Hif stabilisation (Kajimura et al., 2006; Manchenkov et al., 2015;
Santhakumar et al., 2012)
Hydroxylase
inhibition
Addition to embryo water of:
Cobalt chloride Hif stabilisation (Kajimura et al., 2006)
Dimethyloxalylglycine Hif stabilisation (Elks et al., 2013, 2011)
Genetic
manipulation
Arnt morpholino Hif downregulation (Barriga et al., 2013; Prasch et al., 2006)
Dominant constructs:
Dominant active Hif-α Hif stabilisation (Elks et al., 2013, 2011; Harris et al., 2013;
Santhakumar et al., 2012)Dominant negative Hif-α Hif downregulation
Mutant line vhl−/− knockout Hif stabilisation (van Rooijen et al., 2011, 2009)
Transgenic reporter
line
Tg(phd3:GFP)i144 transgenic line Reporter of Hif
signalling
(Santhakumar et al., 2012)
PHD FIHHIF-α HIF-β VHL
Nuclear membrane
Human Zebrafish Human Zebrafish Human ZebrafishHuman Zebrafish Human Zebrafish
(EGLN2)
PHD2
PHD3
Phd2a
Phd1
Phd3
FIH Hif1an VHL VhlHIF-1α
HIF-2α
HIF-3α
Hif-1αa
Hif-1αb
(EPAS1)
Hif-2αa
Hif-2αb
Hif-1αl
Hif-1αl2
HIF-β Arnt1a
U
U
U
U
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PHD FIH
Degraded HIF
HIF-α
OH
VHL
HIF-β
HIF
-α 
deg
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Phd2b
Arnt1b Vll(ARNT1) (HIF1AN)
PHD1
(EGLN1)
(EGLN3)
U
U OH
P300
CBP
HIF-α
HIF-β
HRE HIF target genes
A  Hypoxia signalling homologues
B  Normoxia C  Hypoxia
HIF transcription
factor protein
Proteins that target
HIF for degradation  
Ubiquitin
chain
Hydroxylation
event
CytoplasmCytoplasm
Key
HRE
HIF-responsive
element 
OH OH
Fig. 1. Schematic diagram of the HIF-signalling system and zebrafish homologues. (A) Proteins of the HIF-signalling pathway are illustrated, with HIF
proteins in green and proteins that target HIF for degradation in red. The human isoforms are listed, with their zebrafish counterparts in blue text. (B) In normoxia,
the hydroxylase enzyme PHD and the VHL protein target HIF-α for ubiquitination in the cytoplasm and subsequent degradation by the proteasome. A second
hydroxylase enzyme, FIH, hydroxylates a C-terminal asparagine residue on HIF-α in normoxia to repress the transactivation function of HIF. (C) In hypoxia,
hydroxylase enzymes are silenced, and HIF translocates to the nucleus and binds its cofactors, where it upregulates target gene expression by binding to HREs in
their regulatory regions. Abbreviations: CBP, CREB-binding protein; FIH, factor inhibiting HIF; HIF, hypoxia-inducible factor; HREs, HIF-responsive elements;
P300, E1A binding protein; PHD, prolyl hydroxylase domain-containing proteins; VHL, von Hippel-Lindau.
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et al., 2013; Greenald et al., 2015; Kajimura et al., 2006; Kulkarni
et al., 2010; Santhakumar et al., 2012).
Manipulation of hypoxia signalling in zebrafish
The genetic conservation of HIF-signalling components across
vertebrates means that in vivo studies in simpler vertebrates, such as
in murine models and zebrafish, have relevance to human hypoxia
signalling. Zebrafish are highly amenable to pharmacological and
genetic manipulation, and these properties have led to the creation of
a number of methods to modulate Hif signalling in vivo (Fig. 2). The
benefits of modulating Hif in the zebrafish include being able to
follow the effects and any resulting disease-related processes in an
intact organism, from the whole-body response down to the level of
individual cells and cell types.
Physical hypoxia
The classical cellular models employed to investigate HIF
signalling use physical hypoxia. In cell-line and tissue-culture
systems, this relatively simple procedure can be performed in a
hypoxic chamber. However, hypoxia is not simple to achieve when
using in vivomurine models because of their large size and the need
to feed and care for the animals while in the chamber (Hancher and
Smith, 1975). Zebrafish embryos are much smaller than mice
(2-5 mm across) and do not need to feed until after 5 days
postfertilisation. They can therefore be treated much like a cell-
culture model and can be left undisturbed in a hypoxic chamber for
prolonged periods of time (Manchenkov et al., 2015; Santhakumar
et al., 2012). Zebrafish embryos are relatively tolerant to low
oxygen, but care should be taken to balance the carbon dioxide
levels to ensure that pH remains neutral. Any media used should
also be pre-incubated in low oxygen before their addition to the
embryos to ensure that low oxygen levels are maintained. A level of
5% hypoxia is sufficient to activate Hif signalling in the zebrafish,
and this level has been used to demonstrate that downstream Hif-α
targets are conserved (Kajimura et al., 2006; Santhakumar et al.,
2012). Brief incubation periods have demonstrated that zebrafish
embryos are amenable to hypoxic preconditioning that is protective
against later hypoxic events, a phenomenon observed in mammals
that is not currently understood (Manchenkov et al., 2015).
Pharmacological inhibition of oxygen-sensing hydroxylases
The treatment of zebrafish with small molecular pharmaceuticals is
a powerful means by which to manipulate genetic pathways and
enzyme activity in vivo. The liquid environment of zebrafish larvae
facilitates the temporal manipulation of pathways through the
addition of drugs direct to the embryo media. Drugs can also be
added and washed off repeatedly. The small size of zebrafish
embryos allows medium- to high-throughput drug screening in a
96-well plate format, making zebrafish a powerful screening
model (Kaufman et al., 2009; Robertson et al., 2014a). The best-
characterised pharmaceuticals used to manipulate HIF-α
are pan-hydroxylase inhibitors that inhibit PHD and FIH
hydroxylase family members to stabilise HIF-α (Robinson et al.,
2008). The hydroxylase inhibitors cobalt chloride (CoCl2) and
A  Hydroxylase inhibition
HIF target genes
FIH
HIF-α
HIF-α
HIF-β
VHL
HIF target genes
HIF target genes
HIF target genes
HIF target genes
PHD3 GFP
HIF-α
Immersion in
DMOG or
CoCl2
PHD
Microinjection of
RNA or DNA or morpholino
into one-cell stage embryo
Raise to stage of interest
Silencing of hydroxylase enzymes
X
Male Female
Heterozygotes or homozygotes
Raise to stage of interest
Dominant active Hif-α
Dominant negative Hif-α
Arnt1(Hif-β) morpholinoHif-α stabilised
HIF-α
Hif-α stabilised
Vhl mutant
Tg(phd3:GFP) reporter line
Hif-α truncated protein
C  Transgenic lines
Hif-α stabilised
OHOH OH
B  Genetic manipulation
Fig. 2. Manipulation of hypoxia signalling in zebrafish. (A) The zebrafish is amenable to in vivo pharmacological manipulation, which enables evaluation of the
effects of Hif-signalling modulation and any resultant disease-related processes in an intact organism. Drugs such as DMOG and cobalt chloride can be added
directly to the embryo water to inhibit the hydroxylase enzymes Phd and Fih, thus allowing the expression of Hif target genes in normoxia. Zebrafish embryos can
be used for testing many drugs at a time because individual embryos can fit into a 96-well plate format. (B) Hif signalling can be manipulated genetically in
zebrafish embryos by microinjection of RNA or DNA constructs or antisense oligonucleotide morpholinos targeting Hif-pathway components into the one-cell
stage. The injection of dominant active Hif-α constructs can be used to stabilise Hif-α, because in these constructs the regulatory proline targets of Phd and the
asparagine target of Fih are mutated into non-hydroxylatable amino acids. Dominant negative Hif-α variants, instead, contain truncations that remove the
transactivation domains required for signal transduction. In addition, morpholinos against the Hif-1β/Arnt subunits can successfully knock down Hif signalling.
(C) Transgenic lines are available to manipulate and follow Hif signalling in vivo. Notably, the vhl−/− mutants can upregulate Hif signalling via Hif-α stabilisation,
whereas the Tg(phd3:GFP)i144 transgenic line can be used as a reporter of Hif activity. Abbreviations: Arnt, aryl hydrocarbon nuclear translocator; DMOG,
dimethyloxalylglycine; Fih, factor inhibiting HIF; GFP, green fluorescent protein; HIF, hypoxia-inducible factor; Phd, prolyl hydroxylase domain-containing
proteins; phd3, prolyl hydroxylase domain-containing protein-3; vhl, von Hippel-Lindau.
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dimethyloxalylglycine (DMOG) have been used in the zebrafish
systems to control Hif-α stabilisation temporally (Elks et al.,
2013, 2011; Kajimura et al., 2006; Fig. 2A). However, CoCl2 has to
be used at high concentrations (10 mM) to achieve hydroxylase
inhibition and has been shown to have off-target toxic effects in
fish (Saeedi Saravi et al., 2009). DMOG is a more specific
2-oxalylglycine hydroxylase inhibitor and is less toxic than
CoCl2. Nonetheless, it is important to consider that, like CoCl2,
DMOG is a pan-hydroxylase inhibitor and will have effects on
biological processes independently of Hif. Both treatments stabilise
Hif-α in the zebrafish model and induce downstream target gene
expression (e.g. transcription of phd3; Elks et al., 2011; Kajimura
et al., 2006).
Genetic manipulation and visualisation of Hif-α signalling
Targeting Hif-α genetically is a powerful and specific approach to
studying the roles of Hif signalling in disease. Morpholinos
(blocking antisense oligonucleotides) against Hif-1αb and Arnt
subunits have been successfully used in zebrafish embryo models to
knock down Hif signalling (Barriga et al., 2013; Prasch et al., 2006;
Fig. 2B). Morpholinos are limited by off-target, non-specific events,
estimated to occur in up to 50% of morpholinos (Kok et al., 2015).
To circumvent these off-target effects, dominant active and
dominant negative hif-α constructs have been created to
manipulate Hif signalling in vivo (Elks et al., 2011; Fig. 2B).
These constructs are based on manipulation of HIF-α in human cell-
line models (Chan et al., 2005; Linke et al., 2004; Manotham et al.,
2005). Dominant negative Hif-α variants contain truncations (of
∼330 amino acids) that remove the N-terminal and C-terminal
transactivation domains (N-TAD and C-TAD) required for signal
transduction. They downregulate Hif signalling by binding to
cofactors (such as Hif-1β), but being unable to transduce a signal.
Dominant active Hif-α variants are inherently stable, even in
normoxia, because the regulatory proline targets of Phd have been
mutated into non-hydroxylatable amino acids (along with the
asparagine target of Fih, which lifts the transcriptional block
mediated by Fih). Dominant constructs can be expressed transiently
over all tissues of the embryo through the injection of synthesised
RNA at the one-cell stage without any overt signs of off-target
expression or toxicity (Elks et al., 2011, 2013; Harris et al., 2013).
A major advantage of modulating Hif-α using dominant variants
is that they can be driven in specific tissues of interest, using
tissue- and cell-type-specific promoters or the GAL4/UAS (yeast
transcription activator protein/upstream activation sequence) system
(Elks et al., 2011, 2013, 2014; Jopling et al., 2012).
Efficient knockout technologywasdeveloped in the zebrafish in the
early 2000s, based on random mutagenesis followed by high-
throughput sequencing (TILLING; Wienholds et al., 2003). Mutant
alleles for vhlwere generated as one of the first knockouts produced by
TILLING and have proved to be a tractable model for studying the
overactivation ofHif signalling in zebrafish (van Rooijen et al., 2009).
Transgenic fluorescent lines are important tools that are used in
zebrafish disease models to investigate biological processes in
different tissue systems, in real time. Santhakumar et al. (2012) took
advantage of transgenic technology to make a hypoxia-signalling
reporter zebrafish line. From gene-expression profiling studies of
the vhl−/− zebrafish mutant, it was noted that phd3 is highly
upregulated in a consistent fashion compared with wild-type and
heterozygous siblings (van Rooijen et al., 2011). By driving green
fluorescent protein (GFP) expression with the phd3 promoter, the
Tg(phd3:GFP)i144 transgenic line provides a read out for hypoxia
and Hif signalling in vivo (Santhakumar et al., 2012). This reporter
line thus allows the functional stabilisation of Hif-α to be imaged in
real time in zebrafish embryos and is an important tool for
investigating the activation of Hif signalling in vivo.
Recent advances in genome-editing technology, including
TALEN (transcription activator-like effector nucleases) and
CRISPR/Cas9 systems (see Box 1), are now enabling the efficient
generation of specific gene knockouts in zebrafish, which are highly
amenable to these technologies (Clark et al., 2011; Hruscha et al.,
2013; Varshney et al., 2015). We are entering an exciting age of
genome editing in vivo; the ability to generate new zebrafish Hif-
signalling mutants using the TALEN and CRISPR genome-editing
technologies is a tantalising future prospect.
Hypoxia signalling in disease: in vivo insights from zebrafish
Hypoxia and HIF signalling play crucial roles in the progression of a
wide range of diseases (Semenza, 2014). The complexity of HIF
activation during in vivo disease processes means that this process is
difficult to model successfully in cell- and tissue-culture assays. For
example, the hypoxic centres of cancerous tumours or tuberculosis
granulomas are not situations that can be modelled easily ex vivo.
The zebrafish has been adopted as a simple whole-vertebrate model
to investigate disease systems, complementing cell and murine
models in the quest to understand the roles of hypoxia in disease
(Fig. 3). Here, we discuss recent insights to have emerged from
studies in zebrafish disease models.
Hypoxia signalling in cancer and angiogenesis
An important HIF-α target is vascular endothelial growth factor
(VEGF; Forsythe et al., 1996; Shweiki et al., 1992), a master
regulator of angiogenesis (Leung et al., 1989). Historically, this
mechanistic link has been drawn from the roles of hypoxia in
tumour vascularisation (Connolly et al., 1989). Tissue hypoxia is a
crucial component of the tumour microenvironment and becomes
evident as a tumour undergoes rapid uncontrolled growth, causing it
to outgrow the local circulation and leading to its centre becoming
hypoxic. Localised HIF-α expression drives expression of VEGF to
increase blood circulation to the centre of the tumour, supporting
further rapid growth. However, excessive VEGF leads to aberrant
vessel formation, leading to vessels that are leaky and inefficient and
that promote the escape of cancer cells and subsequent metastases
(Welti et al., 2013). This has been shown to be true in a zebrafish
model where physical hypoxia increases the dissemination and
invasion of a mouse fibrosarcoma implanted into zebrafish
embryos, with both dissemination and invasion being correlated
with increased VEGF and tumour vascularisation (Lee et al., 2009).
Nonetheless, this model is not without its limitations because
hypoxia is exerted across the whole organism, rather than being the
localised hypoxia that is observed in cancerous tumours. The
development of the Tg(phd3:GFP)i144 line has enabled the
visualisation of localised hypoxic signalling in tumours in vhl−/−
knockout zebrafish at physiological oxygen levels (Santhakumar
et al., 2012). This study was performed in adults, but by using a
combination of transgenic and imaging technologies in embryos,
zebrafish models of tumour hypoxia have the potential to become an
important model for screening therapeutics for cancer studies that
has yet to be exploited. The pharmacological targeting of HIF has
exciting potential as an anti-tumour therapy to limit tumour growth
and decrease metastases. However, this prospect is complicated by
tumour cells adapting to the inhibition of HIF through metabolic
reprogramming, potentially aiding cancer cell survival, making this
treatment strategy something of a double-edged sword (Golinska
et al., 2011).
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The ease of imaging intersegmental vessels has made the
zebrafish a valuable model for studying angiogenesis, both in
development and in cancer studies (Lawson and Weinstein, 2002).
Intersegmental vessels are blood vessels that run between the somite
muscle blocks of the embryonic zebrafish connecting the major
vessels at the dorsal and ventral sides of the trunk. The direct
transcriptional regulation of VEGF by HIF, as well characterised in
mammals, has been demonstrated in zebrafish (Maeda et al., 2008).
Using bright fluorescent transgenic lines that mark vessel endothelia
[e.g. the Tg(fli:GFP) transgenic line], it has been shown that the
potentially clinically relevant anti-angiogenic properties of methyl
tert-butyl ether, with a previously unknown mechanism of action,
are a result of the downregulation of Hif- and Vegf-dependent
angiogenesis (Bonventre et al., 2013). More recently, the direct
HIF-VEGF link has been investigated and applied to other disease
situations that are not traditionally associated with angiogenesis. In
a naturalised zebrafish model of tuberculosis (usingMycobacterium
marinum infection), it has been demonstrated that inhibition of
vascular invasion into developing granulomas reduces bacterial
growth and dissemination within the host and might be a novel
therapeutic approach to reduce tuberculosis infection in humans
(Oehlers et al., 2015).
As well as the direct link between HIF and VEGF, the zebrafish
model has identified more subtle regulatory mechanisms of
angiogenesis in disease. The vhl−/− mutant has been used as a
convenient model of Hif-driven angiogenesis and has identified
additional regulatory mechanisms of angiogenesis, which are
independent of Vegf (van Rooijen et al., 2010, 2009). Using the
vhl−/− model, it was demonstrated that hypoxia-mediated
angiogenesis differs from developmental angiogenesis in its need
for the presence of blood flow (Watson et al., 2013). The validation
of the vhl−/− mutant as a robust model for hypoxia-driven
angiogenesis has provided a clinically relevant model for vascular
retinopathies (eye disorders caused by persistent or acute damage to
the retina; van Rooijen et al., 2011, 2010). Apart from its role in HIF
turnover, VHL is also a tumour suppressor, the loss of which causes
VHL-associated polycythaemia disease (an increase in red blood
cell count; see Box 1) in humans (Pastore et al., 2003). The vhl−/−
zebrafish mutant has been used as a tractable animal model for its
Hif-dependent functions in the development of polycythaemia (van
Rooijen et al., 2009).
Hypoxia signalling in inflammation and tissue regeneration
Tissue hypoxia can occur following injury as blood vessels become
damaged and blood oxygen delivery to the local region is restricted
(Manresa et al., 2014). Tissue injury causes inflammation and the
recruitment of immune cells into the wound to clear damaged cells
and to protect against infection. Innate immune cells (leukocytes) are
the first cells to respond to tissue injury or infection (Palazon et al.,
2014) and must be able to sense local oxygen changes, rapidly
adapting to these changing conditions to operate in areas of low
oxygen tension. Inflammation is necessary for tissue repair, but must
resolve in order for tissue regeneration and homeostasis. HIF
signalling plays a crucial role in the regulation of inflammation,
because it contributes to the regulation of the lifespan and immune
activityof leukocytes (Hannah et al., 1995). Inflammation also acts to
promoteHIF via nuclear factorκ-light-chain-enhancer of activatedB
cells (NFκB; see Box 1), demonstrating the tight molecular link
between signalling systems (Jung et al., 2003). The tissue damage
observed in inflammatory diseases, such as in chronic obstructive
pulmonary disease (COPD; Box 1), can be seen as a result of the
failure of timely resolution of inflammation (Hallett et al., 2008;
Walmsley et al., 2011). It was previously thought that removal of
neutrophils during resolution of inflammation was exclusively
regulated by the death of neutrophils by apoptosis (Haslett et al.,
1994) and their subsequent clearance by macrophage efferocytosis.
A zebrafish model of neutrophil inflammation using a sterile tailfin
transection (Fig. 3C) has allowed the investigation of a new
mechanism for neutrophil removal from inflammatory sites: the
reverse migration of neutrophils (Elks et al., 2011; Renshaw et al.,
2006). Although the idea of immune cells migrating away from
wound sites has been identified in other vertebrate models, it has
proved challenging to characterise definitively (Buckleyet al., 2006).
In the transparent zebrafish model, in vivo real-time observations
B  Cell-to-cell response C  Individual cell responseA  Whole-organism response 
Transcriptomic profiling of
gene expression, e.g. heat map
of vhl–/– embryos versus 
wild-type siblings 
e.g. macrophage (red), neutrophil
(green) and mycobacterial (blue)
interactions in vivo
e.g. neutrophil (green) inflammation
at a tailfin injury (dashed red line)
WT vhl–/–
G
en
e 
ex
pr
es
si
on
20 µm 200 µm
Zebrafish embryo
Fig. 3. Zebrafish as amodel to investigate the role of Hif in disease. (A) Transcriptional profiling in zebrafish vhl−/−mutant embryos has been used to observe
the response to overactivation of Hif signalling at the whole-organism level. (B) Complex cell type-cell type interactions can be studied in situations where Hif
is activated, taking advantage of fluorescent transgenic lines that label specific groups of cells, e.g. in macrophage, neutrophil and bacterial interactions.
(C) Zebrafish can also be used to investigate individual cell behaviours, such as the behaviour of neutrophils at a site of inflammation (e.g. tailfin transection).
1354
REVIEW Disease Models & Mechanisms (2015) 8, 1349-1360 doi:10.1242/dmm.021865
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
have shown that reversemigration and apoptosis operate in parallel to
the resolution of inflammation and can both be manipulated by
changes in Hif signalling (Elks et al., 2011; Holmes et al., 2012;
Mathias et al., 2006; Robertson et al., 2014a; Yoo and Huttenlocher,
2011). The stabilisation ofHif-α signalling in the zebrafishmodel, by
DMOGor by genetic stabilisation of hif-1αb or hif-2αa, can delay the
process of reverse migration, decrease neutrophil apoptosis and
thereby delay the resolution of inflammation (Elks et al., 2011;
Thompson et al., 2014). Importantly, the relevance of the zebrafish
model to human disease was demonstrated by the replication of two
naturally occurring gain-of-function humanHIF-2αmutations in the
zebrafish. G487R and G487W mutations in zebrafish Hif-2αa
phenocopied a neutrophil apoptosis phenotype observed in people
with the equivalent gain-of-function mutations (Thompson et al.,
2014). The recognition of reverse migration as a potential anti-
inflammatory approach has opened up newavenues of potential drug
treatments for currently untreatable inflammatory diseases (Lucas
et al., 2014). If the mechanisms of reverse migration could be
identified, then targeting these mechanisms might offer an effective
treatment to alleviate diseases, such as chronic obstructive
pulmonary disease, by removing inflammation, rather than by
treating the symptoms alone. Once inflammation has resolved, tissue
regeneration can occur and homeostasis can be restored.
Hypoxia signalling is integrally involved in all stages of wound
repair and regeneration (Nauta et al., 2014). The regenerative
capacity of the zebrafish is much greater than that of mammals,
making it an attractive vertebrate model of tissue regeneration after
injury (Goessling and North, 2014). This is especially true at
embryonic stages where the liver, heart, eye and fins are able to
regenerate completely after injury, but is also retained into
adulthood in some organs. The regeneration of zebrafish
cardiomyocytes has been shown to be dependent partly on Hif-1α
signalling in adult zebrafish, which can survive and regenerate an
injury of up to 20% of the heart tissue, identifying Hif-1α as a
potential drug target for regenerative medicine (Jopling et al., 2012;
Parente et al., 2013).
Hypoxia signalling in infection
Multidrug resistance is a worldwide problem in bacterial infections,
including infections withMycobacterium tuberculosis (the cause of
tuberculosis) and Staphylococcus aureus (the cause of MRSA)
(Anwar et al., 2009; Janbaz et al., 2012). As with inflammatory
processes, HIF-1α has activating effects on leukocytes during
infection (Peyssonnaux et al., 2005; Zarember and Malech, 2005).
Hypoxia signalling is upregulated in cell-line and in murine
macrophage models of bacterial infection, and HIF-1α
overexpression is known to upregulate the antimicrobial activities
of leukocytes, including phagocytosis, bacterial killing and
leukocyte lifespan (Peyssonnaux et al., 2005; Walmsley et al.,
2006; Zarember and Malech, 2005). Intriguingly, upregulation of
HIF-α in infection can be independent of a decrease in oxygen
tension (Palazon et al., 2014). HIF-α has therefore become
increasingly investigated as a druggable target against bacterial
infections, a strategy that would, in theory, be effective against
multidrug-resistant infections because it targets host, not pathogen,
biology.
Concurrent studies in zebrafish larvae shown that Hif-α
signalling is important in in vivo infection, and is upregulated in
leukocytes when zebrafish are challenged with lipopolysaccharide
(a bacterial wall product) in hypoxia or with M. marinum in
normoxia (Fig. 4; Elks et al., 2013; Liu et al., 2013).Mycobacterium
marinum infection of zebrafish larvae is a well-established
vertebrate tuberculosis model that has informed our understanding
of the human disease (Berg and Ramakrishnan, 2012; Meijer and
van der Vaart, 2014; Stoop et al., 2011). The temporal and spatial
resolution of the live zebrafishM. marinum model has been used to
Control morpholino
irf-8 morpholino
(macrophage 
deficient)
PR
DA Hif-1
DA Hif-1
PR
Mycobacterium marinum mpx:GFP (neutrophils)
Mycobacterium marinum L-plastin (leukocytes) Merge
20 μm
A
B
200 μm
Fig. 4. Hif-1α stabilisation reduces bacterial burden in zebrafish embryos. (A) Zebrafish embryos were infected withMycobacterium marinum (red) at 1 day
postfertilisation by injection into the caudal vein. By 4 days postinfection, foci ofM. marinum (red) are surrounded by infected and uninfected leukocytes (green;
L-plastin antibody staining) in structures known as granulomas. (B) Stabilisation of Hif-1α, using dominant active (DA) Hif-1αb reduces the bacterial burden of
zebrafish embryos compared with phenol red (PR)-injected controls. However, when macrophage numbers are depleted using an antisense oligonucleotide
morpholino to the crucial macrophage transcription factor irf-8 (Li et al., 2011), bacteria are able to proliferate in an uncontrolled manner and dominant active
Hif-1αb stabilisation is powerless to decrease infection. Neutrophils, marked in green (using the Tg(mpx:GFP)i114 transgenic zebrafish line; Renshaw et al.,
2006), have emerging roles in granuloma formation and maintenance, but without macrophages present they cannot control infection alone. Images are from
P.M.E. and A.H.M., unpublished observations.
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demonstrate that Hif-α stabilisation in M. marinum-infected
zebrafish macrophages is transient and rapidly downregulated,
creating permissive conditions for bacterial growth (Elks et al.,
2013). The modulation of Hif-α in zebrafish has demonstrated that
this pathway intricately controls the production of neutrophil nitric
oxide (NO). Overexpression of Hif-1α stimulated inducible nitric
oxide synthase (Nos2a) to produce NO, an important antimicrobial
mechanism of leukocytes during infection (Elks et al., 2013, 2014;
see Box 1). Interestingly, Hif-1α and Hif-2α were found to have
opposing functions on NO production. The stabilisation of Hif-1α
primes neutrophils with increased NO levels, allowing the host to
deal with infection better. Conversely, decreasing Hif-2α increases
neutrophil NO levels (Elks et al., 2013). This complex regulatory
signature of different Hif-α variants demonstrates the need for intact
in vivo models, such as the zebrafish, with immune cells in their
natural tissue environment in order to gain a proper understanding
of the mechanisms involved and their precise effect on infection.
HIF components as therapeutic targets: translational
challenges and future prospects
Tissue hypoxia and HIF signalling have been implicated in many
diseases, making the pathway an attractive target for therapeutic
intervention. Future therapeutic strategies aimed at targeting HIF and
hypoxia signalling to treat diseases such as cancer, inflammation and
infection will depend on having a better understanding of the
underlying biology of these conditions through the use of
physiologically relevant disease models. Targeting such a
fundamental, evolutionarily conserved pathway requires caution,
and much remains to be understood about HIF regulation and its
downstream effects in the whole-organism setting. There remain
challenges to the translatability of hypoxia research into the clinic that
newer models such as the zebrafish, in concert with more traditional
cell-line and murine models, could help to address.
HIF activation or inhibition
In complex disease syndromes, such as cancer, the inhibition of HIF
might prove to be beneficial, whereas in others, such as infection,
HIF activation has potential as a therapy. This ‘double-edged sword’
scenario is especially relevant in vivo, where modulating HIF in
tumour cells may be beneficial , while having opposing, potentially
unwanted effects on tumour-resident immune cells; in vivo zebrafish
models have helped to identify mechanisms by which leukocytes
are crucial effector cells in cancer (Feng et al., 2012). Therefore,
experimental whole-organism models, such as the zebrafish, will
facilitate the elucidation of the overall effect of HIF activation or
inhibition both on the target cell type and on the organism as a
whole.
Therapeutics that specifically target the HIF pathway have been
difficult to identify and synthesise. The idea of downregulatingHIF-α
therapeutically has been around for a number of years, especially in
the anaemia and cancer fields, and has been extensively reviewed
elsewhere (Hu et al., 2013; Koh et al., 2010;Maxwell, 2005).Amajor
drawbackhas been the substantial difficulty in designingHIF-specific
inhibitors owing to the intracellular nature of the protein complex and
the lack of active sites towhich small molecular inhibitors are usually
designed (Scheuermann et al., 2013). Current inhibitors of HIF
signalling in early stages of clinical trials have been identified in
screening studies and have indirect effects on HIF, via signalling
components, including phosphoinositide 3-kinase (PI3K) and
mammalian target of rapamycin (mTOR) (see Box 1), but few have
yet to translate their promising in vitro potential into the clinic (Xia
et al., 2012). As yet, there has been no HIF-specific inhibitor
described in the literature. Although HIF-α proteins are difficult to
target because of the lack of a traditional active site, there has been
recent progress in the development of small molecules that target the
Per-ARNT-Sim (PAS) protein interaction domain of HIF-2α, but not
of HIF-1α, important in the assembly of the HIF complex
(Scheuermann et al., 2013). This is because HIF-2α has a larger
cavity in the PASdomain than doesHIF-1α, providing access towater
or small molecular antagonists (Scheuermann et al., 2009). Although
these drugs are potentially exciting compounds thatmight enable us to
dissect the roles ofHIF-1α versusHIF-2α, their activity in vivo has yet
to be elucidated. They will also be likely to produce off-target effects,
because many proteins contain similar PAS domains. A second
promising method to inhibit HIF-2α is the use of drugs that promote
binding of intracellular iron regulatory protein 1 (IRP1; see Box 1) to
the promoter of HIF-2α (but not HIF-1α) mRNA, repressing
translation (Zimmer et al., 2008). The potential in vivo effectiveness
of this strategy was recently demonstrated in the zebrafish vhl
knockout model, where treatment with this class of drugs improved
the disease phenotype (Metelo et al., 2015).
The prospect of activating and stabilising HIF-α as a therapeutic
has had more success, in terms of both the number of
pharmaceuticals that have been identified and the current status of
translating these into clinical trials (Harten et al., 2010). The
majority of these compounds target the regulatory hydroxylase
enzymes, PHD and FIH, and include hydroxylase inhibitors, such as
DMOG, FG-4497 and JNJ1935 (Barrett et al., 2011; Robinson
et al., 2008). Although these drugs enhance HIF-α stability and
activity, all are pan-hydroxylase inhibitors, so not only do they have
effects on PHD-1, -2 and -3, but they also inhibit other hydroxylase
families, such as collagen hydroxylases (Rose et al., 2011).
Nonetheless, a series of hydroxylase inhibitors are in phase 2 and
phase 3 clinical trials to treat anaemia in chronic kidney disease,
paving the way for these drugs to be tested in other diseases.
Animal models of disease have an important place in the
identification of new HIF-modulating compounds and in
assessment of their toxicity and effectiveness in vivo. The
zebrafish embryo represents a small, cost-effective, in vivo
system, in which drugs can be screened in a 96-well format,
allowing medium-high throughput screening to identify drugs that
target HIF-α. Drug screening in zebrafish embryos has proved to be
a successful approach to identify regulators of physiological or
disease-related processes, including regulators of haematopoietic
stem cell production and of reverse migration of neutrophils away
from a site of inflammation (Kaufman et al., 2009; Robertson et al.,
2014a), but has yet to be used to identify HIF modulators in disease
settings. Small vertebrate disease models would allow the effect of
a drug on a specific mechanism to be investigated in a whole-
organism setting. The use of zebrafish in this way would allow off-
target effects and toxicity to be studied in a simple assay. These
in vivo assays will help to address the challenge of identifying novel
Hif-modulating therapeutics in specific disease settings.
HIF-1α, HIF-2α or HIF-3α
The regulation of the hypoxic response is closely controlled by the
transcription and post-translational stabilisation of HIF-1α, HIF-2α
and HIF-3α to produce the overall HIF-signalling effect (Keith
et al., 2012). The best-understood HIF-α isoform in many disease
settings is HIF-1α (Semenza, 2010). However, the role of HIF-2α
has been implicated in diseases such as repetitive kidney cancer for
more than a decade (Kondo et al., 2003; Zimmer et al., 2004). The
differential roles of HIF-1α, HIF-2α and HIF-3α in disease are not
well understood, at least in part because either physical hypoxia or
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hydroxylase inhibition is widely used as a stimulus in studies of HIF
signalling. These methods stabilise all HIF-α variants, whereas in
disease situations variant-specific stabilisation might occur in a
spatial and temporal manner. Although there are well-characterised
targets of HIF-α signalling [for example, erythropoietin, VEGF,
PHD3 and nitric oxide synthase (NOS); see Box 1], there are
potentially >1000 other direct and secondary targets of this
pathway, many of which will be HIF-α-variant and cell-type
specific (D’Angelo et al., 2003; Greenald et al., 2015; Liu et al.,
1995; Palmer et al., 1998; Wang and Semenza, 1993). The zebrafish
has well-conserved Hif-1α, Hif-2α and Hif-3α variants and given its
genetic tractability and the range of diseases that can be modelled, it
offers an opportunity to understand the interplay between HIF-α
variants during disease in real time. Recent data from zebrafish have
demonstrated that Hif-1α and Hif-2α have opposing effects on the
production of NO by leukocytes (Elks et al., 2013). This is one
example of many potential differential responses of HIF-α variants
during disease. The ease with which the zebrafish can be genetically
manipulated has increased our knowledge of the lesser-known
Hif-3α variant, allowing investigation of its multiple splice variants
in the setting of a simple organism, opening up unexplored
possibilities of investigating the role of Hif-3α in disease settings
(Kajimura et al., 2006; Zhang et al., 2014). With increased use of
deep-sequencing techniques from a limited starting material, the
identification of specific Hif-α variant targets during disease, in a
cell-type-specific manner, is now a technical possibility in zebrafish
models of disease (Rougeot et al., 2014). Understanding these finely
balanced mechanisms will be important for the ultimate
development of successful HIF-based therapeutics.
Targeting HIF in a cell-type-specific manner
Exciting advances in drug-delivery technology mean that any
detrimental off-target or unwanted effects caused by HIF-
modulating therapeutics could be avoided by the direct delivery of
a drug to the effector cell type of choice. In humans, one of the most
advanced organ-specific drug-delivery technologies is the targeting
of the liver using liposomes (see Box 1). Liposomes accumulate at
high levels in the liver when administered systemically, potentially
as a result of the liver vasculature having many dead ends (Lorenzer
et al., 2015; Nair et al., 2014). There has been progress in knocking
down HIF signalling using a small interfering (si)RNA against HIF-
1β in hepatic cell lines and, although this has yet to be transferred
into in vivo systems, it remains an exciting therapeutic possibility in
human disease, using liposome-delivery technology (Choi et al.,
2014).
Drug-delivery technologies have recently been successfully
adapted in in vivo zebrafish models, using liposomes and
synthetic polymersomes (a class of artificial vesicles; see Box 1)
to deliver cargos to leukocytes (Fenaroli et al., 2014; Robertson
et al., 2014b; Ruyra et al., 2014). These studies show a promising
indication that HIF manipulation could be performed specifically in
cell types of choice. However, more in vivo work must be done to
develop this technology further and to expand the number of cell
types that could be targeted for HIF manipulation.
Conclusions
Hypoxia and HIF signalling play an integral role in disease
processes, and in vivo studies have identified complex regulatory
systems that involve an interplay between multiple HIF variants and
different cell types that work together to elicit effects. Further
studies of HIF signalling and its associated diseases in in vivo
models are required to understand these complex processes and to
identify potential therapeutic avenues. The zebrafish has emerged as
an exciting and potentially translatable vertebrate model, in which to
investigate the roles of HIFs in disease. Recent advances in genetic
manipulation (CRISPR/Cas9) and microscopy [including lightsheet
and single plane illumination microscopy (SPIM) techniques; see
Box 1] further strengthen the zebrafish as a model (Kobitski et al.,
2015). Although the investigation of Hif in zebrafish is relatively
recent, important discoveries in these models mark out zebrafish as
being an exciting future tool for understanding the complexities of
HIF regulation during disease. Alongside cell and murine models,
zebrafish will help in the search for therapeutic strategies to
modulate HIF effectively in human disease.
Competing interests
The authors declare no competing or financial interests.
Author contributions
P.M.E. performed the experiments shown in Fig. 4. All authors contributed to the
writing of the manuscript.
Funding
P.M.E. is funded by a Sir Henry Dale Fellowship jointly funded by theWellcome Trust
and the Royal Society (Grant Number 105570/Z/14/Z) and a University of Sheffield
Vice-Chancellor’s Fellowship. S.A.R. is funded by an MRC Programme Grant
(MR/M004864/1) and MRC Centre Grant (G0700091). A.H.M. is funded by a Smart
Mix Program of the Netherlands Ministry of Economic Affairs and the Ministry of
Education, Culture and Science. S.A.R. and A.H.M. are funded by a European
Marie-Curie Initial Training Network FishForPharma (PITN-GA-2011-289209).
S.R.W. is funded by a Wellcome Trust Senior Clinical Fellowship (098516). F.J.v.E.
is funded by a European Commission FP7 (HEALTH-F4-2010-242048).
References
Anwar, S., Prince, L. R., Foster, S. J., Whyte, M. K. B. and Sabroe, I. (2009). The
rise and rise of Staphylococcus aureus: laughing in the face of granulocytes. Clin.
Exp. Immunol. 157, 216-224.
Barrett, T. D., Palomino, H. L., Brondstetter, T. I., Kanelakis, K. C., Wu, X., Haug,
P. V., Yan, W., Young, A., Hua, H., Hart, J. C. et al. (2011). Pharmacological
characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-
pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-
inducible factor prolyl hydroxylase inhibitor. Mol. Pharmacol. 79, 910-920.
Barriga, E. H., Maxwell, P. H., Reyes, A. E. and Mayor, R. (2013). The hypoxia
factor Hif-1alpha controls neural crest chemotaxis and epithelial to mesenchymal
transition. J. Cell Biol. 201, 759-776.
Berg, R. D. and Ramakrishnan, L. (2012). Insights into tuberculosis from the
zebrafish model. Trends Mol. Med. 18, 689-690.
Berra, E., Roux, D., Richard, D. E. and Pouyssegur, J. (2001). Hypoxia-inducible
factor-1 alpha (HIF-1 alpha) escapes O(2)-driven proteasomal degradation
irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2,
615-620.
Bonventre, J. A., Kung, T. S., White, L. A. and Cooper, K. R. (2013). Manipulation
of the HIF-Vegf pathway rescues methyl tert-butyl ether (MTBE)-induced vascular
lesions. Toxicol. Appl. Pharmacol. 273, 623-634.
Bruick, R. K. and McKnight, S. L. (2001). A conserved family of prolyl-4-
hydroxylases that modify HIF. Science 294, 1337-1340.
Buckley, C. D., Ross, E. A., McGettrick, H. M., Osborne, C. E., Haworth, O.,
Schmutz, C., Stone, P. C. W., Salmon, M., Matharu, N. M., Vohra, R. K. et al.
(2006). Identification of a phenotypically and functionally distinct population of
long-lived neutrophils in a model of reverse endothelial migration. J. Leukoc. Biol.
79, 303-311.
Chan, D. A., Sutphin, P. D., Yen, S.-E. and Giaccia, A. J. (2005). Coordinate
regulation of the oxygen-dependent degradation domains of hypoxia-inducible
factor 1 alpha. Mol. Cell. Biol. 25, 6415-6426.
Choi, S. H., Chung, A. R., Kang,W., Park, J. Y., Lee, M. S., Hwang, S.W., KimDo,
Y., Kim, S. U., Ahn, S. H., Kim, S. et al. (2014). Silencing of hypoxia-inducible
factor-1beta induces anti-tumor effects in hepatoma cell lines under tumor
hypoxia. PLoS ONE 9, e103304.
Clark, K. J., Voytas, D. F. and Ekker, S. C. (2011). A TALE of two nucleases: gene
targeting for the masses? Zebrafish 8, 147-149.
Connolly, D. T., Heuvelman, D. M., Nelson, R., Olander, J. V., Eppley, B. L.,
Delfino, J. J., Siegel, N. R., Leimgruber, R. M. and Feder, J. (1989). Tumor
vascular permeability factor stimulates endothelial cell growth and angiogenesis.
J. Clin. Invest. 84, 1470-1478.
1357
REVIEW Disease Models & Mechanisms (2015) 8, 1349-1360 doi:10.1242/dmm.021865
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Cramer, T., Yamanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman,
N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V. et al. (2003). HIF-1alpha is
essential for myeloid cell-mediated inflammation. Cell 112, 645-657.
D’Angelo, G., Duplan, E., Boyer, N., Vigne, P. and Frelin, C. (2003). Hypoxia up-
regulates prolyl hydroxylase activity: a feedback mechanism that limits HIF-1
responses during reoxygenation. J. Biol. Chem. 278, 38183-38187.
Egg, M., Koblitz, L., Hirayama, J., Schwerte, T., Folterbauer, C., Kurz, A.,
Fiechtner, B., Most, M., Salvenmoser, W., Sassone-Corsi, P. et al. (2013).
Linking oxygen to time: the bidirectional interaction between the hypoxic signaling
pathway and the circadian clock. Chronobiol. Int. 30, 510-529.
Elks, P. M., van Eeden, F. J., Dixon, G., Wang, X., Reyes-Aldasoro, C. C.,
Ingham, P. W., Whyte, M. K. B., Walmsley, S. R. and Renshaw, S. A. (2011).
Activation of hypoxia-inducible factor-1alpha (Hif-1alpha) delays inflammation
resolution by reducing neutrophil apoptosis and reverse migration in a zebrafish
inflammation model. Blood 118, 712-722.
Elks, P. M., Brizee, S., van der Vaart, M., Walmsley, S. R., van Eeden, F. J.,
Renshaw, S. A. and Meijer, A. H. (2013). Hypoxia inducible factor signaling
modulates susceptibility to mycobacterial infection via a nitric oxide dependent
mechanism. PLoS Pathog. 9, e1003789.
Elks, P. M., van der Vaart, M., van Hensbergen, V., Schutz, E., Redd, M. J.,
Murayama, E., Spaink, H. P. andMeijer, A. H. (2014). Mycobacteria counteract a
TLR-mediated nitrosative defense mechanism in a zebrafish infection model.
PLoS ONE 9, e100928.
Ema, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y. and Fujii-Kuriyama, Y.
(1997). A novel bHLH-PAS factor with close sequence similarity to hypoxia-
inducible factor 1alpha regulates the VEGF expression and is potentially involved
in lung and vascular development. Proc. Natl. Acad. Sci. USA 94, 4273-4278.
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O’Rourke, J.,
Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A. et al. (2001).
C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that
regulate HIF by prolyl hydroxylation. Cell 107, 43-54.
Fenaroli, F., Westmoreland, D., Benjaminsen, J., Kolstad, T., Skjeldal, F. M.,
Meijer, A. H., van der Vaart, M., Ulanova, L., Roos, N., Nystrom, B. et al.
(2014). Nanoparticles as drug delivery system against tuberculosis in zebrafish
embryos: direct visualization and treatment. ACS Nano 8, 7014-7026.
Feng, Y., Renshaw, S. and Martin, P. (2012). Live imaging of tumor initiation in
zebrafish larvae reveals a trophic role for leukocyte-derived PGE(2).Curr. Biol. 22,
1253-1259.
Flinn, L., Bretaud, S., Lo, C., Ingham, P. W. and Bandmann, O. (2008). Zebrafish
as a new animal model for movement disorders. J. Neurochem. 106, 1991-1997.
Forsythe, J. A., Jiang, B. H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D. and
Semenza, G. L. (1996). Activation of vascular endothelial growth factor gene
transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16, 4604-4613.
Goessling, W. and North, T. E. (2014). Repairing quite swimmingly: advances in
regenerative medicine using zebrafish. Dis. Model. Mech. 7, 769-776.
Golinska, M., Troy, H., Chung, Y.-L., McSheehy, P. M., Mayr, M., Yin, X., Ly, L.,
Williams, K. J., Airley, R. E., Harris, A. L. et al. (2011). Adaptation to HIF-1
deficiency by upregulation of the AMP/ATP ratio and phosphofructokinase
activation in hepatomas. BMC Cancer 11, 198.
Greenald, D. J., Jeyakani, J., Pelster, B., Sealy, I., Mathavan, S. and van Eeden,
F. J. (2015). Genome-wide mapping of Hypoxia-inducible factor 1 alpha binding
sites in zebrafish. BMC Genomics (in press).
Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. and Bradfield, C. A.
(1998). Molecular characterization and chromosomal localization of a third alpha-
class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 7, 205-213.
Hallett, J. M., Leitch, A. E., Riley, N. A., Duffin, R., Haslett, C. and Rossi, A. G.
(2008). Novel pharmacological strategies for driving inflammatory cell apoptosis
and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 29,
250-257.
Hampton-Smith, R. J. and Peet, D. J. (2009). From polyps to people: a highly
familiar response to hypoxia. Ann. N. Y. Acad. Sci. 1177, 19-29.
Hancher, C. W. and Smith, L. H. (1975). A normobaric hypoxia facility for preparing
polycythemic mice for assay of erythropoietin. Lab. Anim. Sci. 25, 39-44.
Hannah, S., Mecklenburgh, K., Rahman, I., Bellingan, G. J., Greening, A.,
Haslett, C. and Chilvers, E. R. (1995). Hypoxia prolongs neutrophil survival in
vitro. FEBS Lett. 372, 233-237.
Harris, J. M., Esain, V., Frechette, G. M., Harris, L. J., Cox, A. G., Cortes, M.,
Garnaas, M. K., Carroll, K. J., Cutting, C. C., Khan, T. et al. (2013). Glucose
metabolism impacts the spatiotemporal onset and magnitude of HSC induction in
vivo. Blood 121, 2483-2493.
Harten, S. K., Ashcroft, M. and Maxwell, P. H. (2010). Prolyl hydroxylase domain
inhibitors: a route to HIF activation and neuroprotection. Antioxid. Redox Signal.
12, 459-480.
Haslett, C., Savill, J. S., Whyte, M. K. B., Stern, M., Dransfield, I. and Meagher,
L. C. (1994). Granulocyte apoptosis and the control of inflammation. Philos.
Trans. R. Soc. Lond. B Biol. Sci. 345, 327-333.
Holmes, G. R., Dixon, G., Anderson, S. R., Reyes-Aldasoro, C. C., Elks, P. M.,
Billings, S. A., Whyte, M. K. B., Kadirkamanathan, V. and Renshaw, S. A.
(2012). Drift-diffusion analysis of neutrophil migration during inflammation
resolution in a Zebrafish model. Adv. Hematol. 2012, 792163.
Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C. and
Schmid, B. (2013). Efficient CRISPR/Cas9 genome editing with low off-target
effects in zebrafish. Development 140, 4982-4987.
Hu, Y., Liu, J. andHuang, H. (2013). Recent agents targeting HIF-1alpha for cancer
therapy. J. Cell Biochem. 114, 498-509.
Huang, L. E., Arany, Z., Livingston, D. M. and Bunn, H. F. (1996). Activation of
hypoxia-inducible transcription factor depends primarily upon redox-sensitive
stabilization of its alpha subunit. J. Biol. Chem. 271, 32253-32259.
Huang, L. E., Gu, J., Schau, M. and Bunn, H. F. (1998). Regulation of hypoxia-
inducible factor 1alpha is mediated by an O2-dependent degradation domain via
the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95, 7987-7992.
Janbaz, K. H., Qadir, M. I., Ahmad, B., Sarwar, A., Yaqoob, N. and Masood, M. I.
(2012). Tuberculosis: burning issues: multidrug resistance and HIV-coinfection.
Crit. Rev. Microbiol. 38, 267-275.
Jopling, C., Sune, G., Faucherre, A., Fabregat, C. and Izpisua Belmonte, J. C.
(2012). Hypoxia induces myocardial regeneration in zebrafish. Circulation 126,
3017-3027.
Jung, Y.-J., Isaacs, J. S., Lee, S., Trepel, J. and Neckers, L. (2003). IL-1beta-
mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies
HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17,
2115-2117.
Kaelin, W. G., Jr and Ratcliffe, P. J. (2008). Oxygen sensing by metazoans: the
central role of the HIF hydroxylase pathway. Mol. Cell 30, 393-402.
Kajimura, S., Aida, K. and Duan, C. (2006). Understanding hypoxia-induced gene
expression in early development: in vitro and in vivo analysis of hypoxia-inducible
factor 1-regulated zebra fish insulin-like growth factor binding protein 1 gene
expression. Mol. Cell. Biol. 26, 1142-1155.
Kallio, P. J., Wilson, W. J., O’Brien, S., Makino, Y. and Poellinger, L. (1999).
Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-
proteasome pathway. J. Biol. Chem. 274, 6519-6525.
Kapitsinou, P. P., Sano, H., Michael, M., Kobayashi, H., Davidoff, O., Bian, A.,
Yao, B., Zhang, M.-Z., Harris, R. C., Duffy, K. J. et al. (2014). Endothelial HIF-2
mediates protection and recovery from ischemic kidney injury. J. Clin. Invest. 124,
2396-2409.
Kaufman, C. K.,White, R. M. and Zon, L. (2009). Chemical genetic screening in the
zebrafish embryo. Nat. Protoc. 4, 1422-1432.
Keith, B., Johnson, R. S. and Simon, M. C. (2012). HIF1alpha and HIF2alpha:
sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 12,
9-22.
Kobitski, A. Y., Otte, J. C., Takamiya, M., Schafer, B., Mertes, J., Stegmaier, J.,
Rastegar, S., Rindone, F., Hartmann, V., Stotzka, R. et al. (2015). An
ensemble-averaged, cell density-based digital model of zebrafish embryo
development derived from light-sheet microscopy data with single-cell
resolution. Sci. Rep. 5, 8601.
Koblitz, L., Fiechtner, B., Baus, K., Lussnig, R. and Pelster, B. (2015).
Developmental expression and hypoxic induction of hypoxia inducible
transcription factors in the zebrafish. PLoS ONE 10, e0128938.
Koh, M. Y., Spivak-Kroizman, T. R. and Powis, G. (2010). HIF-1alpha and cancer
therapy. Recent Results Cancer Res. 180, 15-34.
Kok, F. O., Shin, M., Ni, C.-W., Gupta, A., Grosse, A. S., van Impel, A.,
Kirchmaier, B. C., Peterson-Maduro, J., Kourkoulis, G., Male, I. et al. (2015).
Reverse genetic screening reveals poor correlation between morpholino-induced
and mutant phenotypes in zebrafish. Dev. Cell 32, 97-108.
Kondo, K., Kim,W. Y., Lechpammer, M. andKaelin, W. G., Jr. (2003). Inhibition of
HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1,
e83.
Kopp, R., Koblitz, L., Egg, M. and Pelster, B. (2011). HIF signaling and overall
gene expression changes during hypoxia and prolonged exercise differ
considerably. Physiol. Genomics 43, 506-516.
Kulkarni, R. P., Tohari, S., Ho, A., Brenner, S. and Venkatesh, B. (2010).
Characterization of a hypoxia-response element in the Epo locus of the pufferfish,
Takifugu rubripes. Mar. Genomics 3, 63-70.
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. and Whitelaw, M. L. (2002).
Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch.
Science 295, 858-861.
Lawson, N. D. and Weinstein, B. M. (2002). In vivo imaging of embryonic vascular
development using transgenic zebrafish. Dev. Biol. 248, 307-318.
Lee, S. L. C., Rouhi, P., Jensen, L. D., Zhang, D., Ji, H., Hauptmann, G., Ingham,
P. and Cao, Y. (2009). Hypoxia-induced pathological angiogenesis mediates
tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.
Proc. Natl. Acad. Sci. USA 106, 19485-19490.
Leung, D.W., Cachianes, G., Kuang,W. J., Goeddel, D. V. and Ferrara, N. (1989).
Vascular endothelial growth factor is a secreted angiogenic mitogen.Science 246,
1306-1309.
Li, L., Jin, H., Xu, J., Shi, Y. and Wen, Z. (2011). Irf8 regulates macrophage versus
neutrophil fate during zebrafish primitive myelopoiesis. Blood 117, 1359-1369.
Linke, S., Stojkoski, C., Kewley, R. J., Booker, G. W., Whitelaw, M. L. and Peet,
D. J. (2004). Substrate requirements of the oxygen-sensing asparaginyl
hydroxylase factor-inhibiting hypoxia-inducible factor. J. Biol. Chem. 279,
14391-14397.
1358
REVIEW Disease Models & Mechanisms (2015) 8, 1349-1360 doi:10.1242/dmm.021865
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Liu, Y., Cox, S. R., Morita, T. and Kourembanas, S. (1995). Hypoxia regulates
vascular endothelial growth factor gene expression in endothelial cells:
identification of a 5′ enhancer. Circ. Res. 77, 638-643.
Liu, S., Zhu, K., Chen, N., Wang, W. and Wang, H. (2013). Identification of HIF-
1alpha promoter and expression regulation of HIF-1alpha gene by LPS and
hypoxia in zebrafish. Fish Physiol. Biochem. 39, 1153-1163.
Lokmic, Z., Musyoka, J., Hewitson, T. D. and Darby, I. A. (2012). Hypoxia and
hypoxia signaling in tissue repair and fibrosis. Int. Rev. Cell Mol. Biol. 296,
139-185.
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V. and Winkler, J. (2015).
Going beyond the liver: progress and challenges of targeted delivery of siRNA
therapeutics. J. Control Release 203, 1-15.
Lucas, C. D., Hoodless, L. J. and Rossi, A. G. (2014). Swimming against the tide:
drugs drive neutrophil reverse migration. Sci. Transl. Med. 6, 225fs9.
Maeda, Y., Suzuki, T., Pan, X., Chen, G., Pan, S., Bartman, T. andWhitsett, J. A.
(2008). CUL2 is required for the activity of hypoxia-inducible factor and
vasculogenesis. J. Biol. Chem. 283, 16084-16092.
Manchenkov, T., Pasillas, M. P., Haddad, G. G. and Imam, F. B. (2015). Novel
genes critical for hypoxic preconditioning in Zebrafish are regulators of insulin and
glucose metabolism. G3 5, 1107-1116.
Manotham, K., Tanaka, T., Ohse, T., Kojima, I., Miyata, T., Inagi, R., Tanaka, H.,
Sassa, R., Fujita, T. and Nangaku, M. (2005). A biologic role of HIF-1 in the renal
medulla. Kidney Int. 67, 1428-1439.
Manresa, M. C., Godson, C. and Taylor, C. T. (2014). Hypoxia-sensitive pathways
in inflammation-driven fibrosis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 307,
R1369-R1380.
Mathias, J. R., Perrin, B. J., Liu, T.-X., Kanki, J., Look, A. T. and Huttenlocher, A.
(2006). Resolution of inflammation by retrograde chemotaxis of neutrophils in
transgenic zebrafish. J. Leukoc. Biol. 80, 1281-1288.
Maxwell, P. H. (2005). The HIF pathway in cancer. Semin. Cell Dev. Biol. 16,
523-530.
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway,
R. C., Conaway, J. W. and Ohh, M. (2003). Multiple splice variants of the human
HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase
complex. J. Biol. Chem. 278, 11032-11040.
Maynard, M. A., Evans, A. J., Shi, W., Kim, W. Y., Liu, F.-F. and Ohh, M. (2007).
Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma
progression. Cell Cycle 6, 2810-2816.
Meijer, A. H. and van der Vaart, M. (2014). DRAM1 promotes the targeting of
mycobacteria to selective autophagy. Autophagy 10, 2389-2391.
Metelo, A. M., Noonan, H. R., Li, X., Jin, Y., Baker, R., Kamentsky, L., Zhang, Y.,
van Rooijen, E., Shin, J., Carpenter, A. E. et al. (2015). Pharmacological
HIF2alpha inhibition improves VHL disease-associated phenotypes in zebrafish
model. J. Clin. Invest. 125, 1987-1997.
Moroz, E., Carlin, S., Dyomina, K., Burke, S., Thaler, H. T., Blasberg, R. and
Serganova, I. (2009). Real-time imaging of HIF-1alpha stabilization and
degradation. PLoS ONE 4, e5077.
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q.,
Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S. et al. (2014). Multivalent
N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits
robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961.
Nauta, T. D., van Hinsbergh, V. W. M. and Koolwijk, P. (2014). Hypoxic signaling
during tissue repair and regenerative medicine. Int. J. Mol. Sci. 15, 19791-19815.
Oehlers, S. H., Cronan, M. R., Scott, N. R., Thomas, M. I., Okuda, K. S., Walton,
E. M., Beerman, R. W., Crosier, P. S. and Tobin, D. M. (2015). Interception of
host angiogenic signalling limits mycobacterial growth. Nature 517, 612-615.
Palazon, A., Goldrath, A. W., Nizet, V. and Johnson, R. S. (2014). HIF
transcription factors, inflammation, and immunity. Immunity 41, 518-528.
Palmer, L. A., Semenza, G. L., Stoler, M. H. and Johns, R. A. (1998). Hypoxia
induces type II NOS gene expression in pulmonary artery endothelial cells via
HIF-1. Am. J. Physiol. 274, L212-L219.
Parente, V., Balasso, S., Pompilio, G., Verduci, L., Colombo, G. I., Milano, G.,
Guerrini, U., Squadroni, L., Cotelli, F., Pozzoli, O. et al. (2013). Hypoxia/
reoxygenation cardiac injury and regeneration in zebrafish adult heart. PLoS ONE
8, e53748.
Pastore, Y. D., Jelinek, J., Ang, S., Guan, Y., Liu, E., Jedlickova, K.,
Krishnamurti, L. and Prchal, J. T. (2003). Mutations in the VHL gene in
sporadic apparently congenital polycythemia. Blood 101, 1591-1595.
Peyssonnaux, C., Datta, V., Cramer, T., Doedens, A., Theodorakis, E. A., Gallo,
R. L., Hurtado-Ziola, N., Nizet, V. and Johnson, R. S. (2005). HIF-1alpha
expression regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 115,
1806-1815.
Postlethwait, J. H., Woods, I. G., Ngo-Hazelett, P., Yan, Y.-L., Kelly, P. D., Chu,
F., Huang, H., Hill-Force, A. and Talbot, W. S. (2000). Zebrafish comparative
genomics and the origins of vertebrate chromosomes. Genome Res. 10,
1890-1902.
Prabhakar, N. R. and Semenza, G. L. (2012). Adaptive and maladaptive
cardiorespiratory responses to continuous and intermittent hypoxia mediated by
hypoxia-inducible factors 1 and 2. Physiol. Rev. 92, 967-1003.
Prasch, A. L., Tanguay, R. L., Mehta, V., Heideman, W. and Peterson, R. E.
(2006). Identification of zebrafish ARNT1 homologs: 2,3,7,8-tetrachlorodibenzo-
p-dioxin toxicity in the developing zebrafish requires ARNT1.Mol. Pharmacol. 69,
776-787.
Renshaw, S. A. and Trede, N. S. (2012). A model 450 million years in the making:
zebrafish and vertebrate immunity. Dis. Model. Mech. 5, 38-47.
Renshaw, S. A., Loynes, C. A., Trushell, D. M. I., Elworthy, S., Ingham, P.W. and
Whyte, M. K. B. (2006). A transgenic zebrafish model of neutrophilic
inflammation. Blood 108, 3976-3978.
Robertson, A. L., Holmes, G. R., Bojarczuk, A. N., Burgon, J., Loynes, C. A.,
Chimen, M., Sawtell, A. K., Hamza, B., Willson, J., Walmsley, S. R. et al.
(2014a). A zebrafish compound screen reveals modulation of neutrophil reverse
migration as an anti-inflammatory mechanism. Sci. Transl. Med. 6, 225ra29.
Robertson, J. D., Yealland, G., Avila-Olias, M., Chierico, L., Bandmann, O.,
Renshaw, S. A. and Battaglia, G. (2014b). pH-sensitive tubular polymersomes:
formation and applications in cellular delivery. ACS Nano 8, 4650-4661.
Robinson, A., Keely, S., Karhausen, J., Gerich, M. E., Furuta, G. T. and Colgan,
S. P. (2008). Mucosal protection by hypoxia-inducible factor prolyl hydroxylase
inhibition. Gastroenterology 134, 145-155.
Rojas, D. A., Perez-Munizaga, D. A., Centanin, L., Antonelli, M., Wappner, P.,
Allende, M. L. and Reyes, A. E. (2007). Cloning of hif-1alpha and hif-2alpha and
mRNA expression pattern during development in zebrafish. Gene Expr. Patterns
7, 339-345.
Rose, N. R., McDonough, M. A., King, O. N. F., Kawamura, A. and Schofield,
C. J. (2011). Inhibition of 2-oxoglutarate dependent oxygenases. Chem. Soc.
Rev. 40, 4364-4397.
Rougeot, J., Zakrzewska, A., Kanwal, Z., Jansen, H. J., Spaink, H. P. andMeijer,
A. H. (2014). RNA sequencing of FACS-sorted immune cell populations from
zebrafish infection models to identify cell specific responses to intracellular
pathogens. Methods Mol. Biol. 1197, 261-274.
Ruyra, A., Cano-Sarabia, M., Garcia-Valtanen, P., Yero, D., Gibert, I., Mackenzie,
S. A., Estepa, A., Maspoch, D. and Roher, N. (2014). Targeting and stimulation
of the zebrafish (Danio rerio) innate immune system with LPS/dsRNA-loaded
nanoliposomes. Vaccine 32, 3955-3962.
Rytkonen, K. T., Akbarzadeh, A., Miandare, H. K., Kamei, H., Duan, C., Leder,
E. H., Williams, T. A. and Nikinmaa, M. (2013). Subfunctionalization of cyprinid
hypoxia-inducible factors for roles in development and oxygen sensing. Evolution
67, 873-882.
Rytkonen, K. T., Prokkola, J. M., Salonen, V. and Nikinmaa, M. (2014).
Transcriptional divergence of the duplicated hypoxia-inducible factor alpha
genes in zebrafish. Gene 541, 60-66.
Saeedi Saravi, S. S., Karami, S., Karami, B. and Shokrzadeh, M. (2009). Toxic
effects of cobalt chloride on hematological factors of common carp (Cyprinus
carpio). Biol. Trace Elem. Res. 132, 144-152.
Salceda, S. and Caro, J. (1997). Hypoxia-inducible factor 1alpha (HIF-1alpha)
protein is rapidly degraded by the ubiquitin-proteasome system under normoxic
conditions: its stabilization by hypoxia depends on redox-induced changes.
J. Biol. Chem. 272, 22642-22647.
Santhakumar, K., Judson, E. C., Elks, P. M., McKee, S., Elworthy, S., van
Rooijen, E., Walmsley, S. S., Renshaw, S. A., Cross, S. S. and van Eeden,
F. J. M. (2012). A zebrafishmodel to study and therapeutically manipulate hypoxia
signaling in tumorigenesis. Cancer Res. 72, 4017-4027.
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K. and
Gardner, K. H. (2009). Artificial ligand binding within the HIF2alpha PAS-B
domain of the HIF2 transcription factor. Proc. Natl. Acad. Sci. USA 106, 450-455.
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A.,
Naidoo, J., Longgood, J., Frantz, D. E. et al. (2013). Allosteric inhibition of
hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol. 9, 271-276.
Schipani, E., Ryan, H. E., Didrickson, S., Kobayashi, T., Knight, M. and
Johnson, R. S. (2001). Hypoxia in cartilage: HIF-1alpha is essential for
chondrocyte growth arrest and survival. Genes Dev. 15, 2865-2876.
Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer
biology and therapeutics. Oncogene 29, 625-634.
Semenza, G. L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell
148, 399-408.
Semenza, G. L. (2014). Oxygen sensing, hypoxia-inducible factors, and disease
pathophysiology. Annu. Rev. Pathol. 9, 47-71.
Semenza, G. L. andWang, G. L. (1992). A nuclear factor induced by hypoxia via de
novo protein synthesis binds to the human erythropoietin gene enhancer at a site
required for transcriptional activation. Mol. Cell. Biol. 12, 5447-5454.
Shweiki, D., Itin, A., Soffer, D. and Keshet, E. (1992). Vascular endothelial growth
factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature
359, 843-845.
So, J.-H., Kim, J.-D., Yoo, K.-W., Kim, H.-T., Jung, S.-H., Choi, J.-H., Lee, M.-S.,
Jin, S.-W. and Kim, C.-H. (2014). FIH-1, a novel interactor of mindbomb,
functions as an essential anti-angiogenic factor during zebrafish vascular
development. PLoS ONE 9, e109517.
Stoop, E. J. M., Schipper, T., Rosendahl Huber, S. K., Nezhinsky, A. E.,
Verbeek, F. J., Gurcha, S. S., Besra, G. S., Vandenbroucke-Grauls, C. M. J. E.,
Bitter, W. and van der Sar, A. M. (2011). Zebrafish embryo screen for
1359
REVIEW Disease Models & Mechanisms (2015) 8, 1349-1360 doi:10.1242/dmm.021865
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
mycobacterial genes involved in the initiation of granuloma formation reveals a
newly identified ESX-1 component. Dis. Model. Mech. 4, 526-536.
Thompson, A. A. R., Elks, P. M., Marriott, H. M., Eamsamarng, S., Higgins, K. R.,
Lewis, A., Williams, L., Parmar, S., Shaw, G., McGrath, E. E. et al. (2014).
Hypoxia-inducible factor 2alpha regulates key neutrophil functions in humans,
mice, and zebrafish. Blood 123, 366-376.
Tian, H., McKnight, S. L. and Russell, D. W. (1997). Endothelial PAS domain
protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells.
Genes Dev. 11, 72-82.
Torraca, V., Masud, S., Spaink, H. P. and Meijer, A. H. (2014). Macrophage-
pathogen interactions in infectious diseases: new therapeutic insights from the
zebrafish host model. Dis. Model. Mech. 7, 785-797.
van Rooijen, E., Voest, E. E., Logister, I., Korving, J., Schwerte, T., Schulte-
Merker, S., Giles, R. H. and van Eeden, F. J. (2009). Zebrafishmutants in the von
Hippel-Lindau tumor suppressor display a hypoxic response and recapitulate key
aspects of Chuvash polycythemia. Blood 113, 6449-6460.
van Rooijen, E., Voest, E. E., Logister, I., Bussmann, J., Korving, J., van Eeden,
F. J., Giles, R. H. and Schulte-Merker, S. (2010). von Hippel-Lindau tumor
suppressor mutants faithfully model pathological hypoxia-driven angiogenesis
and vascular retinopathies in zebrafish. Dis. Model. Mech. 3, 343-353.
van Rooijen, E., Santhakumar, K., Logister, I., Voest, E., Schulte-Merker, S.,
Giles, R. and van Eeden, F. (2011). A zebrafish model for VHL and hypoxia
signaling. Methods Cell Biol. 105, 163-190.
Varshney, G. K., Pei, W., LaFave, M. C., Idol, J., Xu, L., Gallardo, V., Carrington,
B., Bishop, K., Jones, M., Li, M. et al. (2015). High-throughput gene targeting
and phenotyping in zebrafish using CRISPR/Cas9.Genome Res. 25, 1030-1042.
Walmsley, S. R., Cowburn, A. S., Clatworthy, M. R., Morrell, N. W., Roper, E. C.,
Singleton, V., Maxwell, P., Whyte, M. K. B. and Chilvers, E. R. (2006).
Neutrophils from patients with heterozygous germline mutations in the von Hippel
Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial
phagocytosis. Blood 108, 3176-3178.
Walmsley, S. R., Chilvers, E. R., Thompson, A. A., Vaughan, K., Marriott, H. M.,
Parker, L. C., Shaw, G., Parmar, S., Schneider, M., Sabroe, I. et al. (2011).
Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic
inflammation in humans and mice. J. Clin. Invest. 121, 1053-1063.
Wang, G. L. and Semenza, G. L. (1993). Desferrioxamine induces erythropoietin
gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications
for models of hypoxia signal transduction. Blood 82, 3610-3615.
Wang, G. L. and Semenza, G. L. (1995). Purification and characterization of
hypoxia-inducible factor 1. J. Biol. Chem. 270, 1230-1237.
Wang, G. L., Jiang, B. H. and Semenza, G. L. (1995). Effect of altered redox states
on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem.
Biophys. Res. Commun. 212, 550-556.
Watson, O., Novodvorsky, P., Gray, C., Rothman, A. M. K., Lawrie, A.,
Crossman, D. C., Haase, A., McMahon, K., Gering, M., Van Eeden, F. J. M.
et al. (2013). Blood flow suppresses vascular Notch signalling via dll4 and is
required for angiogenesis in response to hypoxic signalling. Cardiovasc. Res.
100, 252-261.
Welti, J., Loges, S., Dimmeler, S. and Carmeliet, P. (2013). Recent molecular
discoveries in angiogenesis and antiangiogenic therapies in cancer. J. Clin.
Invest. 123, 3190-3200.
Wenger, R. H. (2002). Cellular adaptation to hypoxia: O2-sensing protein
hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene
expression. FASEB J. 16, 1151-1162.
Wienholds, E., van Eeden, F., Kosters, M., Mudde, J., Plasterk, R. H. A. and
Cuppen, E. (2003). Efficient target-selected mutagenesis in zebrafish. Genome
Res. 13, 2700-2707.
Xia, Y., Choi, H.-K. and Lee, K. (2012). Recent advances in hypoxia-inducible
factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24-40.
Yoo, S. K. and Huttenlocher, A. (2011). Spatiotemporal photolabeling of neutrophil
trafficking during inflammation in live zebrafish. J. Leukoc. Biol. 89, 661-667.
Yu, L. and Hales, C. A. (2011). Long-term exposure to hypoxia inhibits tumor
progression of lung cancer in rats and mice. BMC Cancer 11, 331.
Zarember, K. A. and Malech, H. L. (2005). HIF-1alpha: a master regulator of innate
host defenses? J. Clin. Invest. 115, 1702-1704.
Zhang, P., Yao, Q., Lu, L., Li, Y., Chen, P.-J. and Duan, C. (2014). Hypoxia-
inducible factor 3 is an oxygen-dependent transcription activator and regulates a
distinct transcriptional response to hypoxia. Cell Rep. 6, 1110-1121.
Zimmer, M., Doucette, D., Siddiqui, N. and Iliopoulos, O. (2004). Inhibition of
hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.Mol.
Cancer Res. 2, 89-95.
Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A.,
Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T. et al. (2008). Small-molecule
inhibitors of HIF-2a translation link its 5′UTR iron-responsive element to oxygen
sensing. Mol. Cell 32, 838-848.
1360
REVIEW Disease Models & Mechanisms (2015) 8, 1349-1360 doi:10.1242/dmm.021865
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
